1800 202 8726
Recurrence detection

PET-CT for Breast Cancer — When It Is Ordered and What It Shows

PET-CT is not part of standard breast cancer follow-up. It is ordered when something specific has changed — a rising tumour marker, a new symptom, or an unexpected finding on another test — and your oncologist needs to know whether the cancer has returned and where.

Medically reviewed by Dr. Bharati Devi Gorantla, Medical Oncologist, MBBS · MD · DM (Adyar, Chennai) · ECMO · MRCP SCE (UK) · Last reviewed September 2026

  • Not a routine check — PET-CT is not used for regular surveillance after breast cancer treatment. It is triggered by a specific clinical concern, not a calendar.
  • Markers and symptoms drive it — A rising CA 15-3, CA 27.29, or CEA — or a new symptom like bone pain — is usually what leads your team to request the scan.
  • Reliability depends on your subtype — Some breast cancer types are less visible on PET-CT. Your oncologist factors this in when deciding whether to order it and how to read the result.
  • Scans are coordinated for you — CION arranges PET-CT through partner imaging centres. Your care team manages the referral and reviews the report with you.
4.8 · 800+ Google reviews · 15,000+ patients treated
Limited Slots Today

Get this explained properly

₹950   Today: FREE  ·  Including free written second opinion

Reply within 2 working hours
Report reviewed by a senior oncologist
Confidential. No commitment to start treatment.
or
Call 1800 202 8726
17+
Cancer Specialists
on Panel
96.9%
Breast Cancer
Survival Rate*
15,000+
Patients
Treated
4.8★
Google Rating
(800+ reviews)

PET-CT for breast cancer recurrence is ordered when a rising tumour marker or a new symptom suggests the cancer may have returned — not as a routine check. NCCN and ESMO guidance reserves it for patients with clinical suspicion of recurrence, because in early breast cancer it rarely changes management.

CION does PET-CT in Hyderabad from Rs 10,499 — among the lowest published prices in the city, with no hidden charges. Indicative price, as of September 2026.

What do these terms mean?

Tumour marker
A protein measurable in your blood — CA 15-3, CA 27.29, or CEA — that some breast cancers release. A rising level can be an early signal of recurrence, but it is not a diagnosis on its own. Infection, inflammation, and benign liver conditions can also raise these levels.
Recurrence
Cancer that returns after treatment. Local recurrence means it has come back in the breast, chest wall, or nearby lymph nodes. Distant recurrence means it has spread to another part of the body — most commonly bone, liver, or lungs. Treatment is different for each.
FDG-avid
PET-CT works by detecting cells that absorb a radioactive glucose tracer. Tumours that absorb a lot of it show up brightly on the scan. Some breast cancers — particularly lobular carcinoma and well-differentiated hormone receptor-positive types — absorb less glucose and may not show up clearly even when present.
PET-CT
A scan that combines a metabolic picture (PET) with detailed anatomy (CT) in one appointment. It can show where in the body cells are unusually active and what those areas look like structurally — useful when recurrence may have spread to multiple sites.

When does your oncologist order a PET-CT for breast cancer?

Your team orders a PET-CT when something specific has changed, not as a scheduled surveillance scan. The most common trigger is a tumour marker — CA 15-3, CA 27.29, or CEA — that has been rising across two or more blood tests. A single elevated reading usually leads to a repeat test first.

Symptoms that commonly lead to a PET-CT referral include persistent bone pain, unexplained breathlessness, significant unintentional weight loss, abnormal liver blood tests, and a new lump or palpable lymph node found on examination.

PET-CT is not recommended for routine follow-up in asymptomatic patients after early breast cancer treatment. NCCN, ASCO, and ESMO are consistent on this: without clinical suspicion of recurrence, whole-body scanning adds radiation exposure and a risk of false positives without improving outcomes.

How reliable is PET-CT at finding a breast cancer recurrence?

PET-CT is generally reliable for detecting distant metastases — cancer that has spread to bone, liver, lungs, or distant lymph nodes — when the tumour is metabolically active. For this purpose, it can show more of the picture in a single scan than a bone scan and CT done separately.

Reliability is lower for certain subtypes. Lobular carcinoma and hormone receptor-positive, low-grade tumours tend to absorb less glucose, meaning PET-CT may not show them clearly even when they are present. Your oncologist knows whether this applies to your specific cancer.

PET-CT does not reliably detect brain metastases — MRI is the preferred scan for the brain. It can also miss very small lesions anywhere in the body. A negative result does not completely rule out recurrence; your team will interpret it alongside your markers, symptoms, and other investigations.

Still unclear?

Send your reports across and a specialist will walk you through what they mean — what is known, what is not, and what the options actually are.

PET-CT Partner Centres

PET-CT Scan Centres in Hyderabad

CION offers PET-CT scans through 4 trusted partner PET-CT centres across Hyderabad, so you can choose the one closest to you. Call 18002028726 and we’ll guide you to the earliest available appointment.

These are partner diagnostic centres within the CION network. Toll-free booking: 18002028726.

Meet the Specialists

17+ senior cancer specialists. One panel for your case.

Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.

Dr. Naresh Gundu
Medical Oncologist

Dr. Naresh Gundu

MBBS, DNB (Internal Medicine), DM (Medical Oncology)

View Profile
Dr. C. Raghavendra Reddy
Medical Oncologist

Dr. C. Raghavendra Reddy

MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)

View Profile
Dr. Bharati Devi Gorantla
Medical Oncologist

Dr. Bharati Devi Gorantla

MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)

View Profile
Dr. Owais Mohammed
Medical Oncologist

Dr. Owais Mohammed

MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)

View Profile
Dr. T. Raghavender Reddy
Medical Oncologist

Dr. T. Raghavender Reddy

MBBS, DM (Medical Oncology), MD (Radiation Oncology)

View Profile
Dr. N. Kiranmayee
Medical Oncologist

Dr. N. Kiranmayee

MBBS, DM (Medical Oncology), MD (Internal Medicine)

View Profile
Dr. Muralidhar Muddusetty
Surgical Oncologist

Dr. Muralidhar Muddusetty

MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)

View Profile
Dr. Raghavendra Naik
Surgical Oncologist

Dr. Raghavendra Naik

MBBS, MS (General Surgery), M.Ch (Surgical Oncology)

View Profile
Dr. Mohammed  Imaduddin
Surgical Oncologist

Dr. Mohammed Imaduddin

M.B.B.S, MS (General Surgery), M.Ch (Surgical Oncology)

View Profile
Dr. Vinay Mamidala
Surgical Oncologist

Dr. Vinay Mamidala

MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)

View Profile
Dr. Paila Gowri Naidu
Surgical Oncologist

Dr. Paila Gowri Naidu

MBBS, MS (General Surgery), M.Ch (Surgical Oncology), FMAS

View Profile
Dr. Venkata Sushma P
Radiation Oncologist

Dr. Venkata Sushma P

MBBS, MD (Radiation Oncology)

View Profile
Dr. Kirti Ranjan Mohanty
Radiation Oncologist

Dr. Kirti Ranjan Mohanty

MBBS, MD (Radiation Oncology)

View Profile
Dr. Gangadhar Vajrala
Radiation Oncologist

Dr. Gangadhar Vajrala

MBBS, MD (Radiation Oncology), MPH

View Profile
Dr. Basudev Pokhrel
Hematologist

Dr. Basudev Pokhrel

MBBS, M.D (Immunohematology & Blood Transfusion)

View Profile
Dr. Mohammed Imran
Interventional Radiologist

Dr. Mohammed Imran

View Profile
Dr. Vajja Sandeep Kumar
Surgical Oncologist

Dr. Vajja Sandeep Kumar

MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology

View Profile
Dr. Sridhar Kamani
Surgical Oncologist

Dr. Sridhar Kamani

MBBS, MS (General Surgery), DrNB (Surgical Oncology)

View Profile

Want a specific doctor for your case? Mention them when booking.

Book Free Consultation

Get a straight answer from a specialist

45 minutes, your reports reviewed, your questions answered in plain language.

Book Free Consultation Call 1800 202 8726

What should you tell your team before the scan is arranged?

  • All medications and supplements you are taking, including herbal preparations — some affect how the tracer is absorbed
  • Whether you have diabetes — blood sugar levels change how cells take up the glucose tracer and can alter the scan result
  • Any recent infection, surgery, or procedure — inflammation causes cells to absorb the tracer and can appear as abnormal activity on the scan
  • If you are pregnant or breastfeeding — the radioactive tracer cannot be given without specialist review
  • Any implanted cardiac device, as this affects the CT component of the scan
  • Anxiety about enclosed spaces — the scanner is open-ended, but telling the team in advance means they can prepare to support you

What happens during a PET-CT appointment?

  1. Fasting beforehand

    You will be asked not to eat for several hours before the scan. Drinking plain water is usually allowed. Your team will give you the specific instructions for your appointment.

  2. Tracer injection

    A small amount of radioactive glucose tracer is injected through a cannula in your arm. You then rest quietly for approximately an hour while your body absorbs it. Movement during this waiting period can affect the scan result.

  3. The scan itself

    You lie still on a flat table that moves slowly through the scanner. The combined PET-CT scan typically takes 20 to 30 minutes. It is painless and requires no breath-holding beyond brief pauses the machine guides you through.

  4. After the scan

    The radioactivity fades within a few hours. Drinking water helps clear the tracer from your body. You may be asked to avoid close contact with young children or pregnant women for a short period — your imaging team will tell you how long.

  5. Getting the result

    The scan is reported by a nuclear medicine specialist and reviewed alongside your clinical picture by your oncologist. Your team will discuss what the result means and what the next steps are at your follow-up appointment.

Questions families ask about PET-CT and breast cancer recurrence

My tumour marker has risen. Does that definitely mean the cancer is back?

A rising marker is a signal, not a diagnosis. CA 15-3, CA 27.29, and CEA can rise for reasons other than recurrence — infection, inflammation, benign liver conditions, and other factors all affect these levels. What your oncologist looks at is the trend across multiple readings and whether it is rising alongside other changes in how you feel or what examination shows. A single elevated result usually leads to a repeat blood test before a PET-CT is arranged, unless your wider clinical picture already strongly suggests recurrence.

Can PET-CT miss a recurrence?

Yes. No scan has perfect sensitivity, and PET-CT has specific limitations in breast cancer. Lobular carcinoma and hormone receptor-positive, low-grade cancers tend to absorb little glucose and may not appear clearly even when active. Very small metastases anywhere in the body can also be missed, and brain metastases in particular are more reliably detected with MRI than PET-CT. If your symptoms continue after a negative scan, tell your team. A negative result does not mean your concern has been dismissed — it means the investigation continues.

Why did my doctor order a CT and bone scan instead of PET-CT?

For some breast cancer subtypes and clinical situations, a CT of the chest, abdomen, and pelvis combined with a bone scan gives your team the information they need, and this combination is well-established and widely available. Whether PET-CT adds meaningful information over this depends on your cancer subtype, what the suspected site of recurrence is, and what imaging has already been done. When your oncologist chooses the conventional combination, it is a clinical decision based on what is most likely to help you — not a resource limitation.

The scan found something that may not be cancer. What now?

PET-CT occasionally shows areas of increased tracer uptake that turn out to be inflammation, infection, or a benign condition rather than cancer — this is called a false positive. When this happens, your team may request additional imaging of that specific area, or in some cases a biopsy, to confirm what it is before making any decision. This additional step can feel frightening, but it is exactly the right approach. Treatment decisions for recurrence are always based on confirmed findings, not a scan result alone.

Can PET-CT tell us whether treatment for recurrence is working?

PET-CT is sometimes used to assess response during treatment for metastatic breast cancer — watching whether areas that were active on the scan become less active after therapy. This is a different question from detecting recurrence and is not done routinely; your oncologist will explain when repeat scans are planned and what they are looking for. The timing of a response assessment scan matters, because imaging taken too early in a treatment course can be harder to interpret accurately.

How long does it take to arrange a PET-CT through CION?

CION coordinates PET-CT with partner imaging centres, and the wait depends on availability at the centre serving your location. Your care team will arrange the referral and can give you a realistic timeline. When you attend the appointment, bring your previous scan reports, recent blood test results including your tumour marker readings, and your current medication list — this context helps the nuclear medicine specialist interpret your scan accurately rather than in isolation.

A whole-body PET-CT at CION is Rs 10,499 — among the lowest published prices in Hyderabad — with a free Rs 950 oncologist consultation to talk through your report. Indicative price, as of September 2026.

Explore 100 more PET-CT for Your Cancer Type topics

All PET-CT for Your Cancer Type →

Your next step

Talk to an oncologist about your scan

Your PET-CT report read by a senior oncologist, explained in plain language, with a free 45-minute consultation.

Book Free Consultation Call 1800 202 8726
Common questions

Frequently asked questions

Is PET-CT part of standard breast cancer follow-up?

No. Standard follow-up after breast cancer treatment does not include PET-CT. NCCN, ASCO, and ESMO guidance is consistent: routine imaging of asymptomatic patients has not been shown to improve outcomes and adds unnecessary radiation exposure and the risk of false positives. PET-CT is ordered when there is a specific clinical reason — a rising marker, a new symptom, or a finding on another investigation — not as a scheduled surveillance scan.

What is the difference between a PET-CT and a regular CT for breast cancer?

A regular CT shows anatomy — the size and shape of organs and lymph nodes. PET-CT adds a metabolic layer: it shows where cells in the body are consuming glucose at an unusually high rate, which can reveal cancer activity before a lesion is large enough to appear clearly on CT alone. For detecting spread across multiple sites in one scan, PET-CT generally gives more information. For the brain specifically, MRI remains more accurate than either.

My PET-CT was negative but I still have symptoms. Should I be worried?

Tell your oncologist. A negative PET-CT does not completely rule out recurrence, particularly in breast cancer subtypes that absorb less glucose, and it is not reliable for brain metastases. Persistent unexplained symptoms are worth investigating further even after a negative scan. Your team may recommend imaging focused on the specific area causing concern, monitor your markers more closely, or revisit the question if symptoms change. Do not interpret a negative scan as meaning your symptom has been explained away.

How safe is the radiation from a PET-CT?

PET-CT delivers more radiation than a standard CT because it combines two scans. The dose is considered acceptable when there is a clear clinical reason for the scan. This is one reason the scan is not used for routine surveillance — repeated exposures without clinical justification would accumulate dose without corresponding benefit. If you want to understand the specific dose for your scan, ask the imaging team before the appointment. They can explain it relative to everyday background radiation, which many people find a useful comparison.

Can PET-CT find a recurrence before symptoms appear?

Occasionally, yes — when a rising tumour marker leads your team to investigate before any symptom has developed. In this situation, PET-CT may identify a site of recurrence earlier than conventional imaging would have. However, this is different from using PET-CT for routine screening in asymptomatic patients, which is not recommended by any major guideline body. The scan is most useful when there is already a clinical reason to look — a marker trend or a symptom — rather than as a general early-detection strategy.

What happens if PET-CT confirms the cancer has returned?

Confirmation of recurrence leads to a conversation about treatment options for your specific situation — which depends on where the cancer has returned, your original cancer subtype, what treatment you have already had, and your current health. Local recurrence and distant recurrence are treated differently, and your oncologist will explain what was found, what it means, and what the aims of the recommended treatment are. This is a conversation worth having with a written note or a family member present, as there is a great deal to take in at once.

Call now Book free consultation